Welcome to our dedicated page for OneMedNet SEC filings (Ticker: ONMDW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OneMedNet Corp. filings document the healthcare software company’s public-company disclosures, capital structure, and material events. The record includes 8-K reports on Regulation FD investor presentations, a private placement of common stock and pre-funded warrants, related voting and resale-registration arrangements, and continued-listing compliance matters for its Nasdaq-listed securities.
The filings identify OneMedNet’s common stock and redeemable warrants, including warrants exercisable for common shares, and provide formal disclosure around securities purchase agreements, governance-related voting provisions, exhibits, and market-listing notices. These documents frame the company’s financing activity and reporting obligations alongside its imaging real-world data business.
OneMedNet Corporation reported that Nasdaq has notified the company its common stock no longer meets the $1.00 minimum bid price requirement, after trading below that level for 30 consecutive business days. The company has 180 days, until October 12, 2026, to regain compliance by having its share price at or above $1.00 for at least ten consecutive business days. If it still does not comply, OneMedNet may qualify for an additional 180-day period if it meets other Nasdaq Capital Market listing standards and commits to a plan that may include a reverse stock split. The company notes there is no assurance it will regain or maintain compliance, and failure to do so could result in Nasdaq delisting its shares.
OneMedNet Corporation reported that Nasdaq has notified the company its common stock no longer meets the $1.00 minimum bid price requirement, after trading below that level for 30 consecutive business days. The company has 180 days, until October 12, 2026, to regain compliance by having its share price at or above $1.00 for at least ten consecutive business days. If it still does not comply, OneMedNet may qualify for an additional 180-day period if it meets other Nasdaq Capital Market listing standards and commits to a plan that may include a reverse stock split. The company notes there is no assurance it will regain or maintain compliance, and failure to do so could result in Nasdaq delisting its shares.
OneMedNet Corporation filed its annual report describing a niche business curating regulatory-grade imaging Real World Data for life sciences customers through a federated network of more than 2,130 healthcare sites. The company remains unprofitable, with net losses of $2.8 million in 2025 and $10.1 million in 2024 and an accumulated deficit of about $104.4 million, and its auditors raised substantial doubt about its ability to continue as a going concern. Management highlights a highly regulated, competitive environment, a workforce of roughly 23 employees, and heavy reliance on data privacy, cybersecurity and FDA-quality compliance. During 2025, OneMedNet completed equity financings, insider-led subscriptions and multiple debt-for-equity conversions that together eliminated roughly $11.9 million of current liabilities, which it states equals a 62% reduction in total liabilities outstanding as of year-end 2025, while also detailing extensive regulatory, operational and market risks.
OneMedNet Corporation filed its annual report describing a niche business curating regulatory-grade imaging Real World Data for life sciences customers through a federated network of more than 2,130 healthcare sites. The company remains unprofitable, with net losses of $2.8 million in 2025 and $10.1 million in 2024 and an accumulated deficit of about $104.4 million, and its auditors raised substantial doubt about its ability to continue as a going concern. Management highlights a highly regulated, competitive environment, a workforce of roughly 23 employees, and heavy reliance on data privacy, cybersecurity and FDA-quality compliance. During 2025, OneMedNet completed equity financings, insider-led subscriptions and multiple debt-for-equity conversions that together eliminated roughly $11.9 million of current liabilities, which it states equals a 62% reduction in total liabilities outstanding as of year-end 2025, while also detailing extensive regulatory, operational and market risks.
OneMedNet reported mixed results: operating revenue declined while non-operating items improved the bottom line. Total revenue was $155 thousand for the quarter (subscription $47k; web imaging $108k), down from $227k year-over-year, and gross margin was negative $(241)k. The company recorded net income of $2.98 million for the quarter and $1.08 million for the six months, driven largely by a $3.71 million gain on troubled debt restructurings, realized Bitcoin gains, and fair value adjustments.
Balance sheet and liquidity remain constrained: cash was $122k and Bitcoin fair value $1.598 million (15 units), total assets $2.337 million, and total liabilities fell to $6.177 million from $19.677 million due to debt-to-equity conversions and settlements. Stockholders' deficit improved to $(3.84) million. Management states the cash and Bitcoin balance are not adequate to fund operations for 12 months, raising substantial doubt about going concern and requiring additional financing.